Clearside Biomedical (NASDAQ:CLSD – Get Free Report) is projected to post its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect Clearside Biomedical to post earnings of ($0.13) per share and revenue of $0.29 million for the quarter.
Clearside Biomedical Stock Performance
Shares of CLSD opened at $0.79 on Tuesday. The stock has a fifty day moving average of $0.97 and a two-hundred day moving average of $1.06. The company has a market capitalization of $60.11 million, a PE ratio of -1.76 and a beta of 2.22. Clearside Biomedical has a fifty-two week low of $0.77 and a fifty-two week high of $2.12.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Wednesday, November 13th. Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Friday, November 15th. StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
- Five stocks we like better than Clearside Biomedical
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Differences Between Momentum Investing and Long Term Investing
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What is a penny stock? A comprehensive guide
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
